Trial Profile
NiTraSarc Combined Treatment With Nivolumab and Trabectedin in Patients With Metastatic or Inoperable Soft Tissue Sarcomas - The NiTraSarc Phase II Trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Jul 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Trabectedin (Primary)
- Indications Leiomyosarcoma; Liposarcoma; Soft tissue sarcoma; Synovial sarcoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms NiTraSarc
- 06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 26 May 2023 According to PharmaMar media release, results from this study will be presented at the annual meeting of the American Society of Clinical26 May 2023 Oncology (ASCO), to be held on June 2-6, 2023, both virtually and in situ in Chicago, USA.
- 07 Nov 2022 Status changed from active, no longer recruiting to completed.